{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:27:09Z","timestamp":1791041229964,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.xphs.2018.11.045","type":"journal-article","created":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T10:34:10Z","timestamp":1544265250000},"page":"1890-1895","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Further Evidence Regarding the Important Role of Chlorine Atoms of Aripiprazole on Binding to the Site II Area of Human Albumin"],"prefix":"10.1016","volume":"108","author":[{"given":"Keiki","family":"Sakurama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Imoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruyuki","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitsugu","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Otagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishi","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xphs.2018.11.045_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0031-6997(25)06849-8","article-title":"Molecular aspects of ligand binding to serum albumin","volume":"33","author":"Kragh-Hansen","year":"1981","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/j.xphs.2018.11.045_bib2","first-page":"57","article-title":"Structure and ligand binding properties of human serum albumin","volume":"37","author":"Kragh-Hansen","year":"1990","journal-title":"Dan Med Bull"},{"issue":"11","key":"10.1016\/j.xphs.2018.11.045_bib3","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1023\/A:1012138604016","article-title":"Species differences of serum albumins: I. Drug binding sites","volume":"14","author":"Kosa","year":"1997","journal-title":"Pharm Res"},{"issue":"1-3","key":"10.1016\/j.xphs.2018.11.045_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0165-022X(02)00131-8","article-title":"Species-dependency in chiral-drug recognition of serum albumin studied by chromatographic methods","volume":"54","author":"Fitos","year":"2002","journal-title":"J\u00a0Biochem Biophys Methods"},{"issue":"1","key":"10.1016\/j.xphs.2018.11.045_bib5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1124\/dmd.107.016873","article-title":"Subdomain IIIA of dog albumin contains a binding site similar to site II of human albumin","volume":"36","author":"Kaneko","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.xphs.2018.11.045_bib6","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1016\/j.xphs.2017.04.025","article-title":"Species differences in the binding of sodium 4-phenylbutyrate to serum albumin","volume":"106","author":"Yamasaki","year":"2017","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2018.11.045_bib7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bpc.2013.06.004","article-title":"The location of the high- and low-affinity bilirubin-binding sites on serum albumin: ligand-competition analysis investigated by circular dichroism","volume":"180-181","author":"Goncharova","year":"2013","journal-title":"Biophys Chem"},{"issue":"10","key":"10.1016\/j.xphs.2018.11.045_bib8","doi-asserted-by":"crossref","first-page":"13790","DOI":"10.1021\/acsomega.8b02057","article-title":"Analysis of the binding of aripiprazole to human serum albumin: the importance of a chloro-group in the chemical structure","volume":"3","author":"Sakurama","year":"2018","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.xphs.2018.11.045_bib9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jmb.2005.07.075","article-title":"Structural basis of the drug-binding specificity of human serum albumin","volume":"353","author":"Ghuman","year":"2005","journal-title":"J\u00a0Mol Biol"},{"issue":"6","key":"10.1016\/j.xphs.2018.11.045_bib10","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/j.xphs.2016.03.012","article-title":"Tyrosine411 and Arginine410 of human serum albumin play an important role in the binding of sodium 4-phenylbutyrate to site II","volume":"105","author":"Enokida","year":"2016","journal-title":"J\u00a0Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2018.11.045_bib11","doi-asserted-by":"crossref","first-page":"e87919","DOI":"10.1371\/journal.pone.0087919","article-title":"Differential effects of methoxy group on the interaction of curcuminoids with two major ligand binding sites of human serum albumin","volume":"9","author":"Sato","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.xphs.2018.11.045_bib12","doi-asserted-by":"crossref","first-page":"e71422","DOI":"10.1371\/journal.pone.0071422","article-title":"A\u00a0comprehensive insight into binding of hippuric acid to human serum albumin: a study to uncover its impaired elimination through hemodialysis","volume":"8","author":"Zaidi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.xphs.2018.11.045_bib13","doi-asserted-by":"crossref","first-page":"36782","DOI":"10.1038\/srep36782","article-title":"Artificial blood for dogs","volume":"6","author":"Yamada","year":"2016","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.xphs.2018.11.045_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0021-9258(19)81445-X","article-title":"Removal of fatty acids from serum albumin by charcoal treatment","volume":"242","author":"Chen","year":"1967","journal-title":"J\u00a0Biol Chem"},{"issue":"11","key":"10.1016\/j.xphs.2018.11.045_bib15","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1248\/cpb.36.4377","article-title":"Studies on 2(1H)-quinolinone derivatives as neuroleptic agents I. Synthesis and biological activities of (4-phenyl-1-piperazinyl)-propoxy-2(1H)-quinolinone derivatives","volume":"36","author":"Banno","year":"1988","journal-title":"Chem Pharm Bull"},{"issue":"5","key":"10.1016\/j.xphs.2018.11.045_bib16","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1021\/jm940608g","article-title":"Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives","volume":"41","author":"Oshiro","year":"1998","journal-title":"J\u00a0Med Chem"},{"issue":"1","key":"10.1016\/j.xphs.2018.11.045_bib17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5507\/bp.2015.065","article-title":"Quantification of selected antidepressants and antipsychotics in clinical samples using chromatographic methods combined with mass spectrometry: a review (2006-2015)","volume":"160","author":"Sistik","year":"2016","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"issue":"1-3","key":"10.1016\/j.xphs.2018.11.045_bib18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejphar.2005.02.051","article-title":"Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic","volume":"515","author":"Tadori","year":"2005","journal-title":"Eur J Pharmacol"},{"issue":"1-3","key":"10.1016\/j.xphs.2018.11.045_bib19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2008.09.008","article-title":"Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors","volume":"597","author":"Tadori","year":"2008","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1016\/j.xphs.2018.11.045_bib20","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review","volume":"28","author":"Peuskens","year":"2014","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.xphs.2018.11.045_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","article-title":"The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor","volume":"441","author":"Jordan","year":"2002","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.xphs.2018.11.045_bib22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"15","key":"10.1016\/j.xphs.2018.11.045_bib23","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2165\/00003495-200464150-00010","article-title":"Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder","volume":"64","author":"Swainston Harrison","year":"2004","journal-title":"Drugs"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354918307950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354918307950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T10:40:12Z","timestamp":1775299212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354918307950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0022354918307950"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2018.11.045","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Further Evidence Regarding the Important Role of Chlorine Atoms of Aripiprazole on Binding to the Site II Area of Human Albumin","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2018.11.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}